Chiome Bioscience

4583.T

Tokyo, Japan· Est. 2005

A Japanese public biotech using its proprietary ADLib® system to discover and develop antibody drugs for unmet medical needs, with a focus on oncology.

chiome.co.jp

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

AI Company Overview

A Japanese public biotech using its proprietary ADLib® system to discover and develop antibody drugs for unmet medical needs, with a focus on oncology.

Oncology

Technology Platform

The ADLib® system is a proprietary, in vitro technology for rapidly generating a diverse library of monoclonal antibodies, enabling discovery against challenging targets like membrane proteins without animal immunization.

Opportunities

Opportunities include leveraging the ADLib® platform to discover next-generation antibody formats (e.g., ADCs, multi-specifics) for oncology and expanding strategic partnerships with larger pharma companies for pipeline development.

Risk Factors

Key risks include heavy reliance on a single technology platform, potential challenges in advancing internal pipeline candidates through clinical trials, and competition from larger, global antibody discovery companies.

Competitive Landscape

Chiome competes with global antibody discovery platforms (e.g., AbCellera, BioNTech's acquired capabilities) and other Japanese biotechs. Its differentiation lies in the specific mechanics of the ADLib® system and its integrated 'Intelligence' from running full discovery-to-development programs.

More companies in Japan →